1. The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation

   • Lisa Ann Kraus
   • Shanti K. Samuel
   • Marie Christine Bissery

   OriginalPaper Pages: 259 - 268

2. The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum

   • Seamus O'Reilly
   • Elizabeth O'Hearn
   • Mark E. Molliver

   OriginalPaper Pages: 269 - 279

3. Immunomodulatory effects of docetaxel on human lymphocytes

   • Ming-Sing Si
   • David K. Imagawa
   • Dominic C. Borie

   OriginalPaper Pages: 281 - 290

4. Effect of valspodar on the pharmacokinetics of unbound paclitaxel

   • Albert J. ten Tije
   • Timothy W. Synold
   • Alex Sparreboom

   OriginalPaper Pages: 291 - 298

5. Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical model

   • Donna K. McClish
   • John D. Roberts

   OriginalPaper Pages: 299 - 308

6. Positron emission tomography (PET): Expanding the horizons of oncology drug development

   • Lisa A. Hammond
   • Louis Denis
   • John G. Kuhn

   OriginalPaper Pages: 309 - 340

7. Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma

   • Beverly Drucker
   • Jennifer Bacik
   • Robert Motzer

   OriginalPaper Pages: 341 - 345

8. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*

   • Christian Dittrich
   • Veronique Dieras
   • Pierre Fumoleau

   OriginalPaper Pages: 347 - 352

9. A phase II trial of pemetrexed in patients with metastatic renal cancer

   • R. Thödtmann
   • T. Sauter
   • A.-R. Hanauske

   OriginalPaper Pages: 353 - 358

10. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer

    • Lissandra Dal Lago
    • Marc F. Richter
    • Gilberto Schwartsmann

    OriginalPaper Pages: 359 - 366

11. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer

    • Glenn Liu
    • Kurt Oettel
    • George Wilding

    OriginalPaper Pages: 367 - 372

12. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study

    • Deborah K. Armstrong
    • John A. Blessing
    • Evelyn R. Nunez

    OriginalPaper Pages: 373 - 377